Bristol-Myers Squibb

FDA approves new dosing for Bristol-Myers Squibb's Opdivo
FDA approves new dosing for Bristol-Myers Squibb's Opdivo
Yahoo/Reuters
FDA
Bristol-Myers Squibb
Opdivo
dosing
cancer
melanoma
Flag link:
Bristol losing its I/O talent to the likes of Pfizer, report finds
Bristol losing its I/O talent to the likes of Pfizer, report finds
Biopharma Dive
Bristol-Myers Squibb
Pfizer
Celgene
immuno-oncology
R&D
Flag link:
3 Big Drugmakers Boosting Huge R&D Budgets
3 Big Drugmakers Boosting Huge R&D Budgets
Motley Fool
R&D
Bristol-Myers Squibb
Celgene
JNJ
Flag link:
If Pfizer is itching to make a major deal, Bristol-Myers Squibb is probably on its radar screen
If Pfizer is itching to make a major deal, Bristol-Myers Squibb is probably on its radar screen
Motley Fool
Pfizer
M&A
Bristol-Myers Squibb
Flag link:
Bristol-Myers axes 107 more staffers as it completes an R&D overhaul
Bristol-Myers axes 107 more staffers as it completes an R&D overhaul
Endpoints
Bristol-Myers Squibb
layoffs
R&D
Connecticut
Flag link:
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?
Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?
Motley Fool
Bristol-Myers Squibb
M&A
Nektar Therapeutics
Flag link:
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Forbes
Bristol-Myers Squibb
Nektar Therapeutics
NKTR-214
cancer
Flag link:
More Questions Than Answers For Bristol-Myers
More Questions Than Answers For Bristol-Myers
Forbes
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Bristol claims victory in crucial immunotherapy trial, but results raise some questions
Bristol claims victory in crucial immunotherapy trial, but results raise some questions
Stat
Bristol-Myers Squibb
Opdivo
Yervoy
advanced lung cancer
Flag link:
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Marketwatch
Bristol-Myers Squibb
earnings
Opdivo
Yervoy
advanced lung cancer
Flag link:
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
Biopharma Dive
Bristol-Myers Squibb
Pfizer
Warfarin
real world evidence
RWE
bloodthinners
Eliquis
Flag link:
Bristol-Myers calls on real-world evidence to unseat warfarin
Bristol-Myers calls on real-world evidence to unseat warfarin
Biopharma Dive
Bristol-Myers Squibb
Warfarin
Eliquis
Pfizer
bloodthinners
Flag link:
Opdivo-Yervoy combo 'encouraging' in colorectal cancer
Opdivo-Yervoy combo 'encouraging' in colorectal cancer
Biopharma Dive
Opdivo
Yervoy
Bristol-Myers Squibb
colorectal cancer
Flag link:
Whom Will Pfizer Buy in 2018?
Whom Will Pfizer Buy in 2018?
Motley Fool
Pfizer
M&A
Biogen
Bristol-Myers Squibb
Allergan
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Flag link:
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
melanoma
Flag link:
After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO
After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO
Fierce Pharma
Bristol-Myers Squibb
Eliquis
Pharma CEOs
Giovanni Caforio
Pfizer
JPMHC 2018
Flag link:
2018 Healthcare And Biotech Outlook
2018 Healthcare And Biotech Outlook
Seeking Alpha
AbbVie
Abbott Labs
Amgen
Allergan
AstraZeneca
Gilead Sciences
Bristol-Myers Squibb
Flag link:
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Yahoo/Reuters
Bristol-Myers Squibb
taxes
Flag link:

Pages